On Jul. 30, 2020, Seqirus announced it had begun shipping its portfolio of seasonal influenza vaccines to customers in the U.S. for the 2020/21 influenza season. Seqirus is one of the world’s largest influenza vaccine companies and is well-positioned to supply up to 60 million doses for the U.S. market this year, depending on demand. Seqirus has a broad portfolio of differentiated products for individuals six months of age to adults 65 years and older, presented in pre-filled syringes as well as multi-dose vials.

This year Seqirus will provide FLUAD® (Influenza Vaccine, Adjuvanted), the first-and-only adjuvanted seasonal influenza vaccine approved for adults 65 and older, in addition to FLUAD® Quadrivalent (Influenza Vaccine, Adjuvanted). FLUAD® Quadrivalent contains an additional B strain to help prevent disease caused by all 4 influenza strains represented in the vaccine.3,4 The Seqirus 2020/21 influenza vaccine portfolio also includes FLUCELVAX® QUADRIVALENT (Influenza Vaccine), a cell-based quadrivalent influenza vaccine approved for use in persons 4 years of age and older5 and AFLURIA® QUADRIVALENT (Influenza Vaccine), an egg-based quadrivalent influenza vaccine approved for use in those six months of age and older.

Seqirus produces influenza vaccines across its global manufacturing network, which includes facilities in the U.S., U.K. and Australia. The company has experienced record demand for influenza vaccines across all markets for the upcoming season and has extended production across its three manufacturing sites.